



Letter to the Editor

Occurrence of plasmidic AmpC β -lactamase in a *Salmonella* Typhimurium isolate of equine origin: First report of CMY-2 in animals in Argentina



Sir,

The increase in transferable resistance to third-generation cephalosporins in zoonotic *Salmonella* constitutes a serious public health threat. Resistance to third-generation cephalosporins is mainly due to acquisition of genes encoding extended-spectrum β -lactamases or AmpC β -lactamases. These genes are mainly plasmid-encoded and are transferable into various serovars of *Salmonella* and other enteric bacteria. CMY-type enzymes are the most common plasmid-mediated AmpC β -lactamase among *Enterobacteriaceae* [1]. A variety of plasmids have been shown to carry the *bla*_{CMY-2} gene and some of them may be associated with particular *Salmonella* serotypes from environmental sources. Although CMY-2-producing *Salmonella* have been found in humans and animals in many countries and regions, isolates from animals has not been previously reported in Argentina.

Here we isolated CMY-2-producing *Salmonella* Typhimurium strain 16-10 (ST10-16) from a diarrhoeal stool sample of a race horse in 2010 in Buenos Aires, and the *bla*_{CMY-2}-bearing plasmid was characterised. Identification was carried out using conventional methods, and serotyping was conducted using the Kauffmann–White scheme. The susceptibility profile was determined by disk diffusion test according to Clinical and Laboratory Standards Institute (CLSI) documents M100-S25 and M31-A3. Phenotypic screening for β -lactamases was performed by synergy testing using disks containing 10 μ g clavulanic acid and 300 μ g phenylboronic acid (PBA). A multiplex PCR assay was conducted for the detection of family-specific plasmid-mediated AmpC β -lactamases, and specific primers were used to achieve the complete *bla*_{CMY} gene [2].

To assess the plasmid transferability and the co-transferred resistance determinants, both conjugation and transformation

were attempted by liquid mating and electroporation, respectively. Minimum inhibitory concentrations (MICs) were also determined for the transconjugants and electrotransformants using the broth microdilution assay and were interpreted according to CLSI document M100-S25. Characterisation of the plasmid incompatibility (Inc) group was conducted by PCR-based replicon typing, whilst its molecular weight was estimated by pulsed-field gel electrophoresis (PFGE) analysis of S1 nuclease-digested DNA. PCR mapping and sequencing were used to determine the genetic environment of *bla*_{CMY-2} [2,3]. The sequence type (ST) was determined according to the *Salmonella* multilocus sequence typing (MLST) database (<http://mlst.ucc.ie/mlst/dbs/Senterica>) [accessed 4 September 2015].

By disk diffusion test, ST10-16 was resistant to ampicillin, cefalotin, cefuroxime, cefotaxime, ceftazidime, cefoxitin and ceftiofur, intermediate to tetracycline, ciprofloxacin, nalidixic acid and aztreonam, and susceptible to cefepime, imipenem, meropenem, kanamycin, gentamicin, amikacin, streptomycin, trimethoprim/sulfamethoxazole, chloramphenicol and enrofloxacin. Synergy was only observed between PBA and both cefotaxime and ceftazidime disks, suggesting the presence of an AmpC type β -lactamase. Determination of the AmpC β -lactamase alleles rendered a 462 bp amplicon, which suggested the presence of a coding gene for a CIT cluster. Amplification of the complete *bla*_{CMY} gene resulted in a 1146 bp amplicon identical to *bla*_{CMY-2}. This gene was located on a plasmid of 130 kb, named pST10-16, which was classified as belonging into the IncI1 incompatibility group. The pST10-16 could be transferred by conjugation and electroporation, and a similar resistance profile to β -lactams was observed in the transconjugant and electrotransformant obtained (Table 1). MLST analysis showed that ST10-16 displayed the following allelic profile: 10, 7, 12, 9, 5, 9, 2, which corresponds to ST19. *bla*_{CMY-2} is the prevalent plasmid-mediated AmpC β -lactamase worldwide, frequently associated with IncA/C and IncI1 plasmids. Most of the IncI1 plasmids confer only the *bla*_{CMY}-associated resistance phenotype, whereas IncA/C plasmids confer additional resistance to antibiotics such as chloramphenicol and tetracycline. Recently,

Table 1
Antimicrobial susceptibilities of wild-type, transconjugant and electrotransformant strains.

Strain	MIC (μ g/mL)											
	AMP	CTX	CAZ	FOX	CTX/CLA	CAZ/CLA	NAL	CIP	TET	KAN	AMK	CHL
<i>Salmonella</i> Typhimurium 10-16	≥ 256	256	64	512	128	128	2	0.5	4	0.5	2	4
10-16 TC	≥ 256	256	64	512	32	256	≥ 64	0.5	≥ 32	0.5	2	4
<i>Escherichia coli</i> CAG 12177 ^a	2	1	1	1	0.5	1	≥ 64	0.016	≥ 32	0.25	0.25	4
10-16 EP	≥ 256	32	64	512	16	256	≥ 64	0.5	1	0.5	2	4
<i>E. coli</i> DH5 α ^b	2	1	1	1	1	1	≥ 64	0.06	1	0.25	0.5	4

MIC, minimum inhibitory concentration; AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; FOX, cefoxitin; CLA, clavulanic acid; NAL, nalidixic acid; CIP, ciprofloxacin; TET, tetracycline; KAN, kanamycin; AMK, amikacin; CHL, chloramphenicol; TC, transconjugant; EP, electrotransformant.

^a Transconjugant recipient strain.

^b Electrotransformant recipient strain.

Incl1 plasmids carrying *bla*_{CMY-2} have been identified from isolates of *Escherichia coli* and *S. Typhimurium* in human patients from Argentina and Uruguay [2,4]. In this study, we report the emergence of the *bla*_{CMY-2} gene in *S. Typhimurium* isolated from an animal source, within a transposon-like element. Upstream of *bla*_{CMY-2}, insertion sequence *ISEcp1* was found truncated by *IS1294*. This *IS1294b*– Δ *ISEcp1*–*bla*_{CMY-2} segment [5] showed 99% similarity with the *bla*_{CMY-2} context identified in pTN38148 (GenBank accession no. FM246883.1) and pR7AC (GenBank accession no. KF434766), both Incl1 plasmids isolated from *E. coli*. A similar arrangement was also found in *E. coli* isolated from equine harbouring an IncFII plasmid pEQ011 (GenBank accession no. KF582523). To our knowledge, the arrangement of this work was not previously described in *Salmonella*. The genetic organisation downstream of *bla*_{CMY-2} (*blc*–*sugE*–*ecnR* genes) was in good agreement with previously reported flanking regions [2].

Taking into account that *S. Typhimurium* ranks among the most prevalent causes of human and animal salmonellosis, and that ST19 is the major contributor to *S. Typhimurium* reported, the emergence of transferable AmpC β -lactamase recovered from animals is a public health concern. Altogether, these results suggest that a plasmid carrying *bla*_{CMY-2} could be disseminating among *Salmonella* and *E. coli* strains. Considering the wide diversity of Incl1 group plasmids and the genetic context associated with *bla*_{CMY-2}, the spread of this mechanism appears to be related both to the mobilisation of transposable elements and the spread of a specific plasmid or clone. To the best of our knowledge, this is the first report describing *Salmonella* from animals capable of producing transferable AmpC β -lactamase in Argentina, and even in South America.

Funding

This work was supported by a grant from Fondo para la Investigación Científica y Tecnológica (FONCyT), Ministerio de Ciencia, Tecnología e Innovación Productiva [PICT 1366 2010]. JED was the recipient of doctoral fellowships from FONCyT and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). GOG and JADC are members of CONICET.

Competing interests

None declared.

Ethical approval

Not required.

Acknowledgments

The authors are grateful to Giovanna Rincon, PhD, and Daniela Cejas, PhD, for their advice in the laboratory work.

References

- [1] Jacoby GA. AmpC β -lactamases. *Clin Microbiol Rev* 2009;22:161–82.
- [2] Cejas D, Fernández Caniglia L, Quinteros M, Giovanakis M, Vay C, Lascialandare S, et al. Plasmid-encoded AmpC (pAmpC) in Enterobacteriaceae: epidemiology of microorganisms and resistance markers. *Rev Argent Microbiol* 2012;44:182–6.
- [3] Sidjabat HE, Sead KY, Coleman L, Sartor A, Derrington P, Heney C, et al. Expansive spread of Incl1 plasmids carrying *bla*_{CMY-2} amongst *Escherichia coli*. *Int J Antimicrob Agents* 2014;44:203–8.
- [4] Cordeiro YL, Yim L, Betancor L, Cejas D, García-Fulgueiras V, Mota MI, et al. Identification of the first *bla*_{CMY-2} gene in *Salmonella enterica* serovar Typhimurium isolates obtained from cases of paediatric diarrhoea illness detected in South America. *J Glob Antimicrob Resist* 2013;1:143–8.
- [5] Yassine H, Bientz L, Cros J, Goret J, Bébéar C, Quentin C, et al. Experimental evidence for *IS1294b*-mediated transposition of the *bla*_{CMY-2} cephalosporinase gene in Enterobacteriaceae. *J Antimicrob Chemother* 2015;70:697–700.

Johana E. Dominguez

Instituto de Patobiología, Centro de Investigación en Ciencias Veterinarias y Agronómicas, Instituto Nacional de Tecnología Agropecuaria, Nicolás Repetto y de los Reseros s/n, 1686 Hurlingham, provincia de Buenos Aires, Argentina

Gabriel O. Gutkind

José A. Di Conza

Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Ciudad Autónoma de Buenos Aires, Argentina

Elsa C. Mercado*

Instituto de Patobiología, Centro de Investigación en Ciencias Veterinarias y Agronómicas, Instituto Nacional de Tecnología Agropecuaria, Nicolás Repetto y de los Reseros s/n, 1686 Hurlingham, provincia de Buenos Aires, Argentina

*Corresponding author. Tel.: +54 11 4621 0443;

fax: +54 11 4621 1712

E-mail address: mercado.elsa@inta.gov.ar (E.C. Mercado).

24 August 2015

Available online 17 October 2015